Gilead Sciences

Gilead Sciences is an American biopharmaceutical company headquartered in Foster City, California, United States. Founded in 1987 as Oligogen by Michael L. Riordan, it focuses on antiviral drugs for HIV/AIDS, hepatitis, influenza, and COVID-19. The company's segments lude HIV (Biktarvy, Descovy), Liver Disease (Livdelzi, Epclusa), Oncology (Trodelvy, Yescarta), and Veklury (COVID-19 treatment). Gilead operates in over 35 countries, with 91% of U.S. product sales through three wholesalers (Cardinal Health, Cencora, McKesson), requiring robust third-party risk management (TPRM) for supply chain integrity under FDA, EMA, and GMP standards. Its TPRM program, per the 2024 10-K, ludes vendor audits for cybersecurity (NIST) and ethical sourcing, with $32 billion in planned U.S. manufacturing investments by 2030 to enhance supply resilience. Gilead acquired CymaBay Therapeutics in 2024 for $4.3 billion, adding seladelpar for PBC, and Interius BioTherapeutics for $350 million to advance CAR T-cell therapies. In Q2 2025, Gilead reported revenues of $7.1 billion, up 2% from Q2 2024, driven by HIV (up 7% to $5.1 billion) and Trodelvy (up 14% to $364 million), offset by Veklury’s 44% decline to $121 million. Non-GAAP EPS was $2.01, flat year-over-year.